NEW YORK (360Dx) – Nightingale Health today announced a strategic collaboration with PerkinElmer to develop precision medicine solutions.
Nightingale said it has developed a biomarker analysis assay based on nuclear magnetic resonance for disease screening, diagnostics, and treatment-efficacy assessment.
Karen Madden, vice president of technology and innovation at PerkinElmer, said in a statement that the firm would work with Nightingale "to develop a comprehensive solution including both Nightingale's innovative assay and PerkinElmer's sequencing services across a range of healthcare applications."
Through its integrated laboratories in the US and India, PerkinElmer offers a genomic lab testing platform that performs newborn screening, diagnostic testing, and genetic sequencing services.
Financial and other terms of the collaboration were not disclosed.
"Until now, metabolomic analyses have been prohibitively expensive and too complex to enable extensive screening, and therefore have failed to keep pace with developments in genomic sequencing," Madden said.
Comprehensive metabolic profiling of blood biomarkers can provide an accurate assessment of the molecular effects of many metabolic diseases, she noted, adding that such profiling can complement genomic information obtained from gene panels, whole-exome sequencing, and whole-genome sequencing.
Teemu Suna, CEO and founder of Nightingale Health, said that during the past two years, the firm has gone through "an extensive R&D and business development phase," and it is now "quickly entering the scale-out phase" of its operations.
Nightingale noted that to pursue further development and commercialization, it raised around €25 million in the last 30 months as equity investments, non-equity loans, and income financing.
In July, the Finnish firm received CE marking for its blood analysis biomarker system for measuring creatinine and glucose.